Acadia Pharmaceuticals (ACAD) Change in Receivables (2013 - 2026)

Acadia Pharmaceuticals' Change in Receivables history runs 14 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 589.48% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $34.6 million (up 1234.21% YoY), while the FY2025 annual figure was $22.7 million, up 1112.92% from the prior year.
• Change in Receivables for Q1 2026 stood at $13.9 million, up from $5.6 million in the prior quarter.
• The five-year high for Change in Receivables was $35.2 million in Q4 2023, with the low at -$18.8 million in Q3 2023.
• The 5-year median for Change in Receivables is $3.4 million (2023), against an average of $4.4 million.
• Peak annual rise in Change in Receivables reached 7208.51% in 2023, while the deepest fall reached 351.99% in 2023.
• Acadia Pharmaceuticals' Change in Receivables stood at $482000.0 in 2022, then surged by 7208.51% to $35.2 million in 2023, then slumped by 117.59% to -$6.2 million in 2024, then jumped by 190.46% to $5.6 million in 2025, then jumped by 147.78% to $13.9 million in 2026.
• Business Quant data shows ACAD's Change in Receivables at $13.9 million in Q1 2026, $5.6 million in Q4 2025, and $8.3 million in Q3 2025.